Haemonetics Corporation

Haemonetics Corporation, headquartered in Boston, Massachusetts, manufactures and supplies blood and plasma management medical devices, hemostasis analyzers, autotransfusion units, vascular closure systems, and associated consumables to federal healthcare agencies exclusively as a prime contractor on a full-and-open, non-set-aside basis. The company holds no SBA certifications and competes across military and civilian health systems without set-aside protection.

Haemonetics operates across a portfolio of 1,799 prime federal awards (100% prime, zero subcontract footprint) with combined potential value of $63.2 million, of which $61.2 million has been obligated. The company draws from a stable installed base of blood management equipment and supplies across federal healthcare networks. Recent representative work includes a $27,474 delivery order from the Department of Health and Human Services in August 2026 for NX orders; a $131,896 purchase order from the Shared Services Center in July 2026 for portable blood analyzers; a $84,000 purchase order from the Defense Health Agency in June 2026 for VASCADE MVP vascular closure components; a $49,691 delivery order from the Department of Veterans Affairs in February 2026 for NX autotransfusion units under the parent $3.8 million IDC (36C10G22D0019); and a five-year $88,770 maintenance agreement from the Bureau of Medicine and Surgery in September 2025 for TEG 5000 hemostasis analyzers at Naval Medical Research Unit San Antonio.

Customer concentration is heavily weighted toward defense healthcare and VA procurement. The top five customers by potential value account for 65% of combined potential value: the Defense Health Agency leads with $16.3 million across 43 awards, followed by the Department of the Navy Bureau of Medicine and Surgery ($8.3 million across 200 awards), the Department of the Army Medical Command ($8.1 million across 106 awards), the Department of Veterans Affairs Headquarters ($6.4 million across 8 awards), and the Defense Logistics Agency Troop Support Medical ($1.8 million across 303 awards). A meaningful volume-versus-dollars divergence appears: DLA Troop Support Medical places 303 orders worth $1.8 million (small-dollar, high-frequency purchases), while the Defense Health Agency places 43 orders worth $16.3 million (larger-dollar, clinical-system orders).

Haemonetics holds position on five named parent vehicles. The largest is Indefinite Delivery Contract N6264505D5021 with 18 task orders valued at $766 thousand, followed by Blanket Purchase Agreement W81XWH12A0014 with 14 task orders valued at $66 thousand, BPA HT001418A0032 with 7 task orders valued at $324 thousand, IDC 36C10G22D0019 (the VA contract noted above) with 5 task orders valued at $248 thousand, and IDC 36C10G19D0008 with 2 task orders valued at $220 thousand. The VA single-award IDC, awarded March 1, 2022, carries a $3.8 million ceiling through February 2027 and consolidates blood management equipment procurement across VA's nationwide medical center network.

Award activity has declined year over year—13 awards in 2022 to 6 in 2026 year-to-date—reflecting mature, sustaining procurement patterns rather than new-market expansion. Only 5 awards (combined potential value $229 thousand) reach ultimate completion within the next twenty-four months, presenting minimal recompete exposure in the near term. The installed base suggests low churn; maintenance and supply replenishment orders dominate the recent pipeline.

Haemonetics competes in primary NAICS categories Surgical and Medical Instrument Manufacturing (431 awards), Biological Product Manufacturing (117 awards), and Medical Equipment and Supplies Merchant Wholesaling (93 awards), with primary PSC Medical and Surgical Instruments, Equipment, and Supplies (1,176 awards). The company maintains five named subsidiaries including Opsens Solutions Inc. (foreign-owned manufacturer), Haemonetics Gesellschaft MIT Beschrankter Haftung, Neoteric Technology LIMITED, 5D Information Management Inc., and Arryx Inc., though the source does not describe their federal roles or capabilities beyond Haemonetics' corporate structure.